Inactief instrument

Andere talen Axovant Sciences Ltd Nyse

Aandelen

AXON

BMG0750W1047

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	02/02
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share	02/02
SIO GENE THERAPIES INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)	06-04-23
Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from S&P TMI Index	27-03-23
Sio Gene Therapies Inc.(OTCPK:SIOX) dropped from NASDAQ Composite Index	22-03-23
Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K	15-03-23
SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	15-03-23
SIO GENE THERAPIES INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	14-02-23
SIO GENE THERAPIES INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14-02-23
Sio Gene Therapies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14-02-23
Sio Gene Therapies Board Approves Plan of Liquidation, Dissolution; Shares Rise After Hours	14-12-22
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution	14-12-22
Sio Gene Therapies : Announces Board Approval of Plan of Complete Liquidation and Dissolution - Form 8-K	14-12-22
SIO GENE THERAPIES INC. : Other Events, Financial Statements and Exhibits (form 8-K)	14-12-22
SIO GENE THERAPIES INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	10-11-22
SIO GENE THERAPIES INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10-11-22
Sio Gene Therapies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10-11-22
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results	10-11-22
Sio Gene Therapies : Failure to Satisfy Listing Rule - Form 8-K	14-09-22
SIO GENE THERAPIES INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	14-09-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Axovant Sciences Ltd Nyse

Aandelen

AXON

BMG0750W1047

Andere talen

Filters